Sperm aneuploidy after testicular cancer treatment: data from a prospective multicenter study performed within the French Centre d’Étude et de Conservation des Oeufs et du Sperme network Nathalie Rives, M.D., Marie Walschaerts, Ph.D., Véronique Setif, Li.Sc., Sylvianne Hennebicq, M.D., Jacqueline Saias, M.D., Florence Brugnon, M.D., Jacques Auger, M.D., Isabelle Berthaut, Ph.D., Ethel Szerman, Ph.D., Myriam Daudin, M.D., Louis Bujan, M.D. Fertility and Sterility Volume 107, Issue 3, Pages 580-588.e1 (March 2017) DOI: 10.1016/j.fertnstert.2016.11.015 Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions
Supplemental Figure 1 An overview of the selection criteria and number of patients enrolled in the study. FISH = fluorescence in situ hybridization; T3, T6, T12, T24 = 3, 6, 12, and 24 months after end of treatment. Fertility and Sterility 2017 107, 580-588.e1DOI: (10.1016/j.fertnstert.2016.11.015) Copyright © 2016 American Society for Reproductive Medicine Terms and Conditions